Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PHASE II NEOADJUVANT STUDY of PD-1 INHIBITOR DOSTARLIMAB (TSR-042) VS. COMBINATION of TIM-3 INHIBITOR COBOLIMAB (TSR-022) and PD-1 INHIBITOR DOSTARLIMAB (TSR-042) in RESECTABLE STAGE III or OLIGOMETASTATIC STAGE IV MELANOMA (NEO-MEL-T)

Next Previous
Trial Profile

PHASE II NEOADJUVANT STUDY of PD-1 INHIBITOR DOSTARLIMAB (TSR-042) VS. COMBINATION of TIM-3 INHIBITOR COBOLIMAB (TSR-022) and PD-1 INHIBITOR DOSTARLIMAB (TSR-042) in RESECTABLE STAGE III or OLIGOMETASTATIC STAGE IV MELANOMA (NEO-MEL-T)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobolimab (Primary) ; Dostarlimab (Primary)
  • Indications Cancer metastases; Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms Neo-MEL-T

Most Recent Events

  • 15 Oct 2025 Status changed from recruiting to active, no longer recruiting.
  • 15 Oct 2025 Planned End Date changed from 15 Apr 2029 to 15 Dec 2029.
  • 05 Nov 2024 Planned number of patients changed from 56 to 62.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top